HYPR · Hyperfine, Inc.
$0.81
+0.00 (+0.10%)
At close · Sep 3
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“The Company’s existing capital resources, including the net proceeds from the recent offerings described below, are expected to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these condensed consolidated financial statements. Unless and until the Company is able to generate a sufficient amount of revenue and generate positive operating cash flows, the Company expects to finance future cash needs through public and/or private offerings of equity securities and/or debt financings. If the Company is not able to obtain additional financing and/or substantially increase revenue from sales, in the longer term, it could result in a substantial doubt about the Company's ability to continue as a going concern. Management believes the net proceeds from the recent offerings, described under Note 9 – “Debt” and Note 10 – “Stockholders’ Equity”, and the Company’s anticipated revenue, provide sufficient liquidity to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$85.97M
Shares
106.05M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.81
Open$0.82
Day$0.79–0.83
52W close$0.81–2.20
Avg vol 30d541K
Short int3.3M · 3.1% float · 5.7d
Short vol73%
Last earningsAug 6, 2026
DataJan 2021–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 9 wks
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$16.54M
Trailing 12 months
Net income (TTM)
−$34.85M
Trailing 12 months
Revenue growth YoY
+44.8%
Year over year
Operating margin
-203.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-32.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$30.22M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+27.8%
Year over year · more shares
Price change (1Y)
-34.6%
Trailing year
Short interest
3.1%
Latest settlement · 5.7 days to cover
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. Hyperfine reported Q2 2026 revenue of $3.9 million (up ~45% YoY) on 12 systems sold (up 50% YoY), with a fourth consecutive quarter of gross margin above 50% and improved cash burn, and reiterated full-year 2026 revenue guidance of $20–$22 million and cash burn guidance of $26–$28 million.
Bullish
- + Q2 revenue rose ~45% YoY to $3.9 million, with 12 systems sold, up 50% YoY.
- + Delivered fourth consecutive quarter of gross margin above 50%, with Q2 gross margin of 50.7%.
- + R&D expenses declined ~15% YoY and cash burn improved both YoY and sequentially, supporting a ~10% projected decline in full-year cash burn.
- + Cash balance increased to $43.5 million and the company expects cash runway to extend into 2028.
- + Reiterated full-year 2026 revenue guidance of $20–$22 million (≈55% growth at midpoint) and gross margin guidance of 50%–55%.
- + International expansion underway with CE/UKCA approvals and first Model 2 systems sold in Europe, plus Indian deployment and French procurement listing.
Bearish
- − Net loss widened slightly to $9.3 million in Q2 2026 from $9.2 million in Q2 2025, including a $0.6 million warrant liability loss.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−32%
below
Price vs 50-day avg
−21%
below
RSI (14)
27
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−18%
trailing
6-month return
−31%
trailing
YTD return
−18%
this year
Relative strength
−46%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+58% holders QoQ · +38 funds added
Insider flow
Distributing
Net -$12.5K over 90 days · 100% sells
Short interest
Rising
3.09% of float · ▲ +10.9% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
82 holders — near 3-yr high, broad support
Squeeze score
54
elevated · 0–100
Fundamentals
Revenue growth
+5%
Y/Y
Gross margin
50%
expanding
EPS growth
+23%
Y/Y
Free cash flow
$-29.1M
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−63%
past year
ATR
6.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Dec 31, 2021
First quarter revenue
· first quarter
$1M
Prior guidance
period ended
· from the Earnings Call filed Dec 31, 2021
Revenue
· fiscal year 2022
$10M – $12M
Cash burn
· 2022
$80M – $90M
Revenue
· first quarter
$1M
Total operating expenses
· for the year
$80M
Guided vs delivered
· last 1 settled
Revenue
fiscal year 2022
guided $10M – $12M
$6.81M
Miss −38.1%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−32%
Bearish
Price vs 50-day avg
−21%
Bearish
RSI (14)
27
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+58% holders QoQ · +38 funds added
Insider flow
Distributing
Net -$12.5K over 90 days · 100% sells
Short interest
Rising
3.09% of float · ▲ +10.9% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
82 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $2
vs 200-day avg -32%
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HYPR
this stock
Hyperfine, Inc.
|
$85.97M | -17.7% | +5.2% | — | 3.1% |
|
ABT
Abbott Laboratories
|
$192.64B | -11.8% | +5.7% | 31.0 | 1.2% |
|
SYK
Stryker Corp
|
$121.41B | -11.2% | +11.2% | 32.8 | 1.8% |
|
MDT
Medtronic plc
|
$117.82B | -4.0% | +8.4% | 24.7 | 1.1% |
|
BSX
Boston Scientific Corp
|
$70.10B | -49.3% | +12.5% | 19.6 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HYPR | -7.2% | -17.8% | -31.1% | -2.2% | -17.7% |
| SPY | -0.1% | -0.6% | +14.9% | -0.3% | +12.2% |
| vs SPY | -7.0% | -17.2% | -46.0% | -2.0% | -29.9% |
Key facts
CIK
1833769
CUSIP
44916K106
13F (30d)
68 filings
67 filers
Visit website
Investor relations